Dun Wang

Dun Wang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Cancer Letters
Verified
Journal Article
Closed access
JTJingling Tang
Jingling Tang
QFQiang Fu
Qiang Fu
YWYongjun Wang
Yongjun Wang
KRKelly Racette
Kelly Racette
DWDun Wang
Dun Wang
FLFeng Liu
Feng Liu

1 June 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
QLQingzhi Lv
Qingzhi Lv
XYXiaoguang Yang
Xiaoguang Yang
MWMenglin Wang
Menglin Wang
JYJincheng Yang
Jincheng Yang
ZQZhilin Qin
Zhilin Qin
ZHZhonggui He
Zhonggui He

10 September 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XYXiao-Guang Yang
Xiao-Guang Yang
LZLan-Cao Zhu
Lan-Cao Zhu
YWYan-Jun Wang
Yan-Jun Wang
YLYan-Yu Li
Yan-Yu Li
DWDun Wang
Dun Wang
Tumor plasticity refers to tumor cell's inherent property of transforming one type of cell to different types of cells. Tumor plasticity is the main cause of tumor relapse, metastasis and drug resistance. Cancer stem cell (CSC) model embodies the trait of tumor plasticity. During carcinoma progression, epithelial-mesenchymal transition (EMT) plays crucial role in the formation of CSCs and vasculogenic mimicry (VM) based on epithelial-mesenchymal plasticity. And the unique tumor microenvironment (TME) not only provides suitable niche for CSCs but promotes the building of CSCs and VM that nourishes tumor tissue together with neoplasm metabolism by affecting tumor plasticity. Therapeutic strategies targeting tumor plasticity are promising ways to treat malignant tumor. In this article, we discuss the recent developments of potential drug targets related to CSCs, EMT, TME, VM, and metabolic pathways and summarize drugs that target these areas in clinical trials.

1 May 2020 in Asian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
RZRuoshi Zhang
Ruoshi Zhang
YZYingxi Zhang
Yingxi Zhang
YZYue Zhang
Yue Zhang
XWXin Wang
Xin Wang
XGXuanming Gao
Xuanming Gao
Yongjun WangYongjun Wang
Yongjun Wang
Although the appearance of Doxil alleviated the cardiotoxicity of DOX, the progression-free survival of patients was not prolonged compared with traditional medication regimens, and side effects such as hand-foot syndrome has occurred. In order to solve this dilemma, we have designed a novel co-delivery strategy to construct a co-loaded liposome of berberine (BER) and doxorubicin (DOX), which was called LipoBeDo. The optimal synergistic ratio of the two drugs was screened by cell cytotoxicity experiments in vitro, and the optimal attenuation ratio was further determined by in vivo cardiac H&E staining pathological sections. The optimal combination treatment caused a robust increase in apoptotic cells of 4T1, as compared to drug alone treatment. The prepared co-loaded liposome, LipoBeDo, had high encapsulation efficiency and good stability. The nanoliposome carrier controlled the biological fate of the drugs and maintained a pre-defined optimal ratio in vivo. The LipoBeDo significantly inhibited tumor growth in 4T1 murine mammary carcinoma model compared with Doxil (P < 0.05), and completely overcame the myocardial rupture toxicity caused by Doxil in mice. Our co-loaded liposome delivery platform technology provided a new direction for the clinical treatment of triple-negative breast cancer and the safe application of DOX.

2 September 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
XYXiaoguang Yang
Xiaoguang Yang
DZDongxue Zhao
Dongxue Zhao
YLYanfeng Li
Yanfeng Li
YLYanyu Li
Yanyu Li
WCWei Cui
Wei Cui
DWDun Wang
Dun Wang
Background: High expression of monoamine oxidase A (MAOA) in non‐small cell lung cancer (NSCLC) is related to epithelial‐mesenchymal transition (EMT) and the development of clinicopathological features of NSCLC. Nevertheless, the role of MAOA in drug resistance still remains unclear. Hence, the aim of this article was to evaluate a previously synthesized MAOA inhibitor (G11) on inhibiting paclitaxel‐resistant NSCLC metastasis and growth.Methods: First, MAOA expression level was evaluated in several NSCLC cell lines. An MTT assay was used to validate the inhibitory effect of G11 on NSCLC cells in vitro. Second, gene expression in G11‐treated H460/PTX cells was analyzed by microarray gene expression. Third, transwell assay was performed to assess the invasion and metastasis of G11‐treated A549/PTX and H460/PTX cells and western blot assay used to analyze vital protein expression level in G11‐treated H460/PTX cells. Finally, the antimetastatic effect of G11 was tested in an NSCLC in vivo model.Results: Our data revealed that G11 significantly inhibited the viability of paclitaxel (PTX)‐resistant NSCLC cell lines (A549/PTX and H460/PTX). G11 dramatically reduced the expression of MAOA in A549/PTX and H460/PTX cells, which exhibited relatively high MAOA expression levels. Additionally, G11 was found to hinder A549/PTX and H460/PTX cell migration and invasion. Furthermore, the in vivo study indicated that the coadministration of G11 and paclitaxel significantly suppressed tumor metastasis in H460/PTX lung metastasis models.Conclusions: These findings indicated G11 showed a moderate inhibitory effect on paclitaxel‐resistant NSCLC metastasis and growth, and support further investigation on MAOA potentially as a promising therapeutic target for paclitaxel‐resistant NSCLC treatment.Key points: Significant findings of the study: Inhibition of MAOA might contribute to the suppression of metastasis and growth in PTX‐resistant NSCLC cells. What this study adds This study explored the potential function of MAOA in drug‐resistant NSCLC and might consider MAOA as a promising target for the treatment of drug‐resistant NSCLC.

1 September 2019 in Fitoterapia
Verified
Journal Article
Closed access
JXJia-Min Xu
Jia-Min Xu
BHBei-Chen Hu
Bei-Chen Hu
LYLei Yuan
Lei Yuan
YWYan-Li Wu
Yan-Li Wu
SLShan-Shan Luan
Shan-Shan Luan
LCLixia Chen
Lixia Chen